13,078 Shares in Liquidia Co. (NASDAQ:LQDA) Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC bought a new position in shares of Liquidia Co. (NASDAQ:LQDA) during the fourth quarter, HoldingsChannel.com reports. The firm bought 13,078 shares of the company’s stock, valued at approximately $154,000.

Several other large investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Liquidia during the 4th quarter valued at $59,000. Walleye Trading LLC increased its stake in Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after buying an additional 4,670 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Liquidia during the fourth quarter valued at about $169,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Liquidia by 43.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock valued at $187,000 after acquiring an additional 5,669 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Liquidia by 20.3% during the fourth quarter. Arizona State Retirement System now owns 15,888 shares of the company’s stock worth $187,000 after purchasing an additional 2,685 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 1.0 %

LQDA stock opened at $15.09 on Friday. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -9.26 and a beta of 0.07. The firm’s fifty day simple moving average is $15.10 and its two-hundred day simple moving average is $12.42.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities research analysts expect that Liquidia Co. will post -1.51 EPS for the current year.

Analyst Upgrades and Downgrades

LQDA has been the subject of several research analyst reports. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC upped their price objective on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Wells Fargo & Company started coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Buy” and an average target price of $26.63.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 2,445 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now owns 267,943 shares of the company’s stock, valued at $3,483,259. This trade represents a 0.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Kaseta sold 23,370 shares of the business’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is currently owned by company insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).